Barclays initiated coverage of Orchestra BioMed (OBIO) with an Overweight rating and $16 price target The firm sees a “series of catalysts” over the next 12-18 months for Orchestra which it expects to drive increasing interest and performance in the “innovative developer of high-impact medical devices.” Orchestra Biomed’s medical technology innovation and commercialization model focuses on developing high-impact medical device therapies through partnerships with large established medical device manufacturers, the analyst tells investors in a research note. Barclays says the company’s pipeline of clinical programs represents an estimated total addressable markets of $14B.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OBIO:
- Orchestra BioMed announces AVIM therapy program presentations
- Orchestra Biomed Reports Q3 2024 Financial Results
- Orchestra BioMed reports Q EPS (41c), consensus (43c)
- OBIO Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
